Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 32, Number 1—January 2026

Research

Clinical Manifestations of Emerging Trichosporon spp. Infections, France

Marie Desnos-OllivierComments to Author , Alexandre Alanio, Maud Gits-Muselli, Karine Boukris-Sitbon, Agathe Bertho, Aude Sturny-Leclère, Emilie Guemas, Philippe Poirier, Christine Bonnal, Marie-Elisabeth Bougnoux, Sophie Brun, Taieb Chouaki, Nicole Desbois-Nogard, Elisabeth Chachaty, Florence Persat, Marc Pihet, André Paugam, Françoise Botterel, Magalie Demar, Loïc Favennec, Florent Morio, Frédéric Gabriel, Arnaud Fekkar, Jean-Pierre Gangneux, Caroline Mahinc, Valérie Letscher-Bru, Laurence Millon, Frédéric Dalle, Julie Bonhomme, Muriel Nicolas, Boualem Sendid, Milène Sasso, Laure Courtellemont, Anne-Laure Roux, Estelle Perraud-Cateau, Juliette Guitard, Edith Mazars, Olivier Lortholary, and Fanny Lanternier
Author affiliation: Institut Pasteur, Paris, France (M. Desnos-Ollivier, A. Alanio, K. Boukris-Sitbon, A. Bertho, A. Sturny-Leclère, O. Lortholary, F. Lanternier); Hôpital Saint-Louis, Paris (A. Alanio); Hôpital Robert Debré, APHP, Université Paris Cité, Paris (M. Gits-Muselli); Université Paris Cité, INSERM, IAME, Paris (M. Gits-Muselli); Centre National de la Recherche Scientifique, Toulouse, France (E. Guemas); Centre Hospitalier Universitaire Clermont-Ferrand, Clermont-Ferrand, France (P. Poirier); Université Blaise Pascal, Clermont-Ferrand (P. Poirier); Hôpital Bichat–Claude-Bernard, Paris (C. Bonnal); Hôpital Necker-Enfants Malades, Paris (M.-E. Bougnoux, O. Lortholary, F. Lanternier); Hôpital Avicenne, Bobigny, France (S. Brun); Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France (T. Chouaki); University Hospital of Martinique, Fort-de-France, Martinique (N. Desbois-Nogard); Gustave Roussy, Villejuif, France (E. Chachaty); Centre Hospitalier Universitaire de Lyon, Lyon, France (F. Persat); CHU d'Angers, University Angers, University Brest, GEIHP, SFR ICAT, Angers, France (M. Pihet); Cochin Port Royal University Hospital AP-AP, Paris (A. Paugam); Université Paris-Est Créteil, Créteil, France (F. Botterel); Centre Hospitalier Andree Rosemon, Cayenne, Guyana (M. Demar); University Hospital Charles Nicolle, Rouen, France (L. Favennec); Nantes University Hospital, Nantes, France (F. Morio); Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France (F. Gabriel); Centre d’Immunologie et des Maladies Infectieuses, Paris (A. Fekkar); Hôpital Pontchaillou, Rennes, France (J.-P. Gangneux); Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France (C. Mahinc); Hôpitaux Universitaires de Strasbourg, Strasbourg, France (V. Letscher-Bru); University Hospital J Minjoz, Besancon, France (L. Millon); Dijon University Hospital, Dijon, France (F. Dalle); Centre Hospitalier Universitaire Côte de Nacre, Caen, France (J. Bonhomme); Centre Hospitalier Universitaire de Guadeloupe, Pointe-à-Pitre, Guadeloupe, France (M. Nicolas); Lille University Hospital Center, Lille, France (B. Sendid); Centre Hospitalier Universitaire Nîmes et Université de Montpellier, Nîmes, France (M. Sasso); Centre Hospitalier Universitaire d’Orléans, Orléans, France (L. Courtellemont); Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France (A.-L. Roux); Centre Hospitalier Universitaire Poitiers, Poitiers, France (E. Perraud-Cateau); Hôpital Saint-Antoine, Paris (J. Guitard); Centre Hospitalier de Valenciennes, Valenciennes, France (E. Mazars)

Main Article

Table 2

Antimicrobial susceptibility profiles of 101 clinical isolates determined by using the EUCAST method, according to species and genotypes recovered, in study of clinical manifestations of emerging Trichosporon species infections, France, 2002–2022*

Species and genotype (no. isolates) MIC50/MIC90, mg/L (range of MICs)
AMB 5FC FLUCO VORI POSA
Trichosporon asahii (52)
 2/>4 (0.25–>4)
 64/>64 (4–>64)
 4/16 (0.25–64)
 0.06/0.25 (<0.015–1)
 0.25/0.5 (<0.015–1)
Genotype 1 (25)
 2/>4 (0.25–>4)
 64/>64 (4–>64)
 4/32 (0.25–64)
 0.125/0.25 (<0.015–1)
 0.25/0.5 (<0.015–1)
Genotype 3 (12)
 1/2 (0.5–4)
 32/>64 (8–>64)
 1 /4 (0.5–8)
 0.06/0.25 (0.03–0.5)
 0.25/0.5 (0.06–0.5)
Genotype 4 (11)
 1/1 (0.25–2)
 32/>64 (8–>64)
 2/4 (0.25–16)
 0.06/0.125 (<0.015–0.25)
 0.06/0.25 (<0.015–0.5)
Genotype 7 (2)
 −/− (2)
 −/− (>64)
 −/− (2–16)
 −/− (0.06–0.5)
 −/− (0.03–0.5)
Genotype 5 (1)
 −/− (4)
 −/− (32)
 −/− (2)
 −/− (0.03)
 −/− (0.25)
Genotype 13† (1)
 −/− (>4)
 −/− (>64)
 −/− (8)
 −/− (0.125)
 −/− (1)
T. austroamericanum (21)
 0.25/1 (0.06–2)
 >64/>64 (64–>64)
 0.5/4 (0.25–4)
 0.03/0.06 (<0.015–0.125)
 0.06/0.25 (<0.015–0.25)
T. inkin (7)
 0.5/− (0.125–>4)
 >64/− (16–>64)
 2/- (1–16)
 0.03/− (<0.015–0.25)
 0.125/− (<0.015–0.5)
T. cf. coremiiforme (2)
 −/− (0.5–2)
 −/− (8–32)
 −/− (0.5–1)
 −/− (0.03–0.125)
 −/− (0.06–0.125)
T. coremiiforme (1)
 −/− (0.5)
 −/− (16)
 −/− (2)
 −/− (0.03)
 −/− (0.125)
T. cf. faecale (4)
 −/− (1–>4)
 −/− (16–>64)
 −/− (1–16)
 −/− (0.03–0.25)
 −/− (0.03–0.5)
T. japonicum (4)
 −/− (0.25–4)
 −/− (8–>64)
 −/− (0.5–4)
 −/− (<0.015–0.125)
 −/− (0.03–0.125)
Cutaneotrichosporon dermatis (4)
 −/− (0.06–0.25)
 −/− (>64)
 −/− (2–16)
 −/− (0.03–0.125)
 −/− (<0.015–0.125)
C. mucoides (1)
 −/− (0.06)
 −/− (8)
 −/− (2)
 −/− (0.125)
 −/− (0.5)
Apiotrichum loubieri (1)
 −/− (1)
 −/− (8)
 −/− (2)
 −/− (0.03)
 −/− (0.06)
A. montevideense (2)
 −/− (0.06–0.25)
 −/− (>64)
 −/− (1)
 −/− (0.03–0.06)
 −/− (0.03–0.125)
A. mycotoxinivorans (2) −/− (2) −/− (16–32) −/− (2–8) −/− (0.125–1) −/− (<0.015–0.25)

*AMB, amphotericin B; cf., putative undescribed species; FLUCO, fluconazole; POSA, posaconazole; VORI, voriconazole; 5FC, flucytosine. †Genotype 13 corresponds to the genotype described previously (GenBank accession no. MN936175)

Main Article

Page created: December 30, 2025
Page updated: January 29, 2026
Page reviewed: January 29, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external